Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
OpenEvidence is partnering with a leading cancer center to embed precision oncology and genomic interpretation into its AI platform, used by nearly a million clinicians. The company also launched a new family of medical AI models—Osler, Sackett, Snow, and Darwin—with Darwin claiming a perfect score on the MedQA benchmark. The goal: a "medical superintelligence" that gives every clinician a world-class specialist team in their pocket.
OpenEvidence is doubling down on oncology, announcing a partnership with an unnamed nationally leading cancer center to integrate expert-curated genomic alteration interpretations directly into its AI platform. The move adds precision oncology decision support to a tool already used by over 690,000 verified U.S. physicians and 915,000 total clinicians, and builds on existing integrations with NCCN and ASCO guidelines.
The company's broader vision is "medical superintelligence"—an ensemble of AI subspecialist agents that together function like a full multispecialty care team. Oncology is the first focus, with genetics, cardiology, and neurology agents slated to follow. Founder Daniel Nadler frames this as a potential equalizer for rural and under-resourced communities that lack access to subspecialty expertise.
Alongside the partnership, OpenEvidence unveiled a new model family named after medical pioneers—Osler (fast, point-of-care), Sackett (evidence-weighted), and Snow (deep literature search)—all rolling out free to verified clinicians today. Its research-preview model, Darwin, claims the first-ever perfect score on the MedQA benchmark.
By the Numbers:
Why it matters: As AI becomes embedded in clinical workflows, tools like OpenEvidence could meaningfully reduce care disparities by giving frontline clinicians—especially in underserved areas—real-time access to subspecialty-level oncology and genomic guidance.
